SB 1625 requires the Oklahoma Insurance Department to conduct a detailed impact analysis for any new law that would mandate changes to health insurance coverage (like adding specific treatments or requiring prior authorization). The analysis must evaluate social impact (public health benefits and affected populations), medical effectiveness (scientific evidence), and financial effects (premium changes and market stability) before such bills can be voted on. The department may hire outside experts for this analysis and must make the reports publicly available online. The bill takes effect November 1, 2026.
SB 207 establishes the Oklahoma Rare Disease Advisory Council within the State Department of Health to address the needs of Oklahomans living with rare diseases (defined as conditions affecting fewer than 200,000 people nationally). The Council, composed of 13 diverse members including patients, caregivers, healthcare providers, researchers, and industry representatives, will conduct public hearings, develop policy recommendations, and create emergency care protocols to improve access to specialists, diagnostics, and equitable treatment. The bill also modifies Oklahoma’s newborn screening program to require an educational initiative for treatable genetic disorders, aiming to prevent intellectual disabilities and reduce infant mortality through early intervention. This legislation directly affects rare disease patients, their families, healthcare providers, and state agencies responsible for public health programs in Oklahoma.
HB 2513, titled the "Oklahoma Mental Health Reform Act of 2025," proposed creating a position requiring an individual with specific qualifications to address the Department of Mental Health and Substance Abuse Services' court-ordered consent decree. The bill specified requirements for this appointee and included an emergency provision. It was scheduled to take effect November 1, 2025, but was pocket-vetoed by the Governor on May 30, 2025, with the veto taking effect June 15, 2025, meaning it never became law. The bill directly affected the Department's compliance with its existing legal agreement but was not enacted.
HB 2645 creates a tax credit for qualifying doctors practicing medicine in rural Oklahoma, directly affecting licensed physicians who meet specific residency and education criteria. The credit, capped at $20,000 per year per doctor, applies to taxable income from medical practice in designated rural areas (population under 25,000 and at least 25 miles from larger cities). The bill includes an annual $1 million total credit limit, with adjustments to prevent exceeding this cap. The bill was pocket-vetoed by the governor on June 15, 2025, and never became law.
HB 1576 requires Oklahoma Medicaid to cover rapid whole genome sequencing (RWGS) for eligible beneficiaries under age 21 with complex or acute illnesses of unknown cause while receiving critical care in a hospital. It mandates coverage only when specific medical criteria are met, such as symptoms suggesting broad genetic testing needs, timely diagnosis being critical for treatment, and conditions like congenital anomalies or abnormal test results. The bill also ensures genetic data used for diagnosis is protected under HIPAA, allows research use only with explicit patient or guardian consent (with opt-out rights), and requires the Oklahoma Health Care Authority to implement rules and seek federal approval for coverage. This policy directly affects Medicaid-covered children and teens in intensive care with undiagnosed conditions.
HB 2298 allows qualified Advanced Practice Registered Nurses (APRNs) in Oklahoma - such as nurse practitioners and nurse-midwives - to prescribe medications independently after meeting specific requirements. To qualify, APRNs must complete 6,240 supervised clinical hours, hold a valid license, and carry $1 million in malpractice insurance per incident. The bill also sets rules for APRN advertising (requiring clear disclosure of their role and scope) and defines supervision requirements for those not yet eligible for independent prescribing. It modifies Oklahoma’s Nursing Practice Act, Pharmacy Act, and Controlled Substances Act to implement these changes.
HB 2584 allows physician assistants (PAs) in Oklahoma to prescribe and administer certain controlled substances under the supervision of a licensed physician, as specified in the Oklahoma Pharmacy Act and Physician Assistant Act. The bill clarifies that pharmacists may dispense these prescriptions only when written by a PA licensed in Oklahoma and supervised by an Oklahoma-licensed physician, and it modifies requirements for practice agreements between PAs and their supervising physicians. It also creates a 9-member Physician Assistant Committee with specific membership rules to oversee PA licensure and practice standards. The law directly affects PAs, supervising physicians, and pharmacists who dispense controlled substances. (Summary based on bill text amendments to Sections 353.1a, 519.2, and 519.3 of Oklahoma statutes.)
SB 574 expands the types of opioid-related projects eligible for state grant funding by allowing the Attorney General to allocate funds toward new prevention, treatment, and recovery initiatives. It directly affects state agencies and community organizations receiving opioid grants by broadening allowable uses beyond current restrictions. The bill authorizes the Attorney General to use grant funds for specific, previously ineligible activities, such as community-based support programs. This policy change modifies how opioid grant funds are distributed without altering the grant application process.
HB 2048, the "340B Nondiscrimination Act," prohibits health insurers, pharmacy benefits managers (PBMs), and third-party payors from discriminating against healthcare providers participating in the federal 340B drug discount program. It specifically bans lower reimbursement rates for 340B drugs, extra fees or administrative burdens for 340B entities, exclusion from provider networks based on 340B status, and requirements to disclose 340B-specific billing details. The law applies to all 340B entities - such as community health centers and hospitals participating in the federal program - and ensures they receive equal treatment in billing, reimbursement, and network access. Enforcement is handled by the Attorney General, with the Oklahoma Medicaid program excluded from these provisions.
HB 2785 requires Oklahoma's Office of Management and Enterprise Services (OMES) to implement stricter budget oversight for the Department of Mental Health and Substance Abuse Services. It mandates OMES to review agency budgets against actual spending before releasing funds, prohibit contracts without clear cost limits, restrict multi-year contract encumbrances to current-year funds, and block payments for unapproved expenses. The bill also requires OMES to report monthly revenue and spending status to the Governor, legislature leadership, and relevant committees. This directly affects state budget management for mental health services by adding specific financial controls to prevent overspending. The law takes immediate effect due to an emergency declaration.
